• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Apollomics Inc.

    11/19/25 4:05:22 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    6-K 1 d38069d6k.htm 6-K 6-K

     

    OMB APPROVAL
    OMB Number:   3235-0116
    Expires:   December 31, 2026
    Estimated average burden
    hours per response   8.7

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of November, 2025.

    Commission File Number 001-41670

     

     

    Apollomics Inc.

     

     

    Not Applicable

    (Translation of registrant’s name into English)

    989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    ☒ Form 20-F   ☐ Form 40-F

     

     
     


    Cayman Litigation Settlement

    On November 19, 2025, Apollomics Inc. (the “Company”) announced that it entered into a settlement agreement (the “Settlement Agreement”) to fully resolve and conclude all matters (the “Settlement”) related to legal proceedings previously filed in the Grand Court of the Cayman Islands by two minority investors in the Company (the “Cayman Litigation”). As described in more detail in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, the Cayman Litigation involved claims issued on July 22, 2024 in the Grand Court of the Cayman Islands by an investment manager on behalf of two minority investors in the Company who had requested the redemption of certain preferred shares of the Company shortly before the Company’s 2023 consummation of the public merger with Maxpro Capital Acquisition Corporation. Please refer to the Company’s press release dated November 19, 2025, furnished as Exhibit 99.1 to this Form 6-K, for more details.

    A stay order had previously been issued on September 12, 2025, as disclosed in a previous Form 6-K filed on September 25, 2025. The Company and the aforementioned minority investors are in the process of submitting the Settlement and Settlement Agreement for the court’s approval to conclude the associated litigation proceedings.

    The information contained in this Form 6-K relating to the Settlement is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Exhibit No.    Description
    99.1    Press Release — Apollomics Announces Settlement of Cayman Litigation

     

    2 of 3


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

           

    APOLLOMICS INC.

            (Registrant)
    Date November 19, 2025        
            (Signature)*
           

    /s/ Peter Lin

            Peter Lin, Chief Financial Officer

     

    SEC 1815 (07-22)    Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

     

    3 of 3

    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apollomics Announces Settlement of Cayman Litigation

    FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement") with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, "TWVC"), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the "Cayman Litigation"). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company's merger with Maxp

    11/19/25 5:38:35 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Changes to its Board of Directors and Composition of Committees

    FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ("Board") and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh's resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh's resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a

    11/17/25 11:00:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

    FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notify

    10/15/25 2:36:10 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    SEC Filings

    View All

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    12/12/25 11:35:36 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    11/19/25 4:05:22 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    11/18/25 11:09:22 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Leadership Updates

    Live Leadership Updates

    View All

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    8/15/24 4:38:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    SC 13G/A - Apollomics Inc. (0001944885) (Subject)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    5/22/24 7:32:01 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Financials

    Live finance-specific insights

    View All

    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

    Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

    3/28/24 7:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

    FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

    3/26/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

    Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

    9/28/23 4:17:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care